ArticleBlood advances2019

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.

Emily M McWilliams et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.